Reported earlier, Knight Therapeutics Sees FY2026 Sales $490.000M-$510.000M vs $465.827M Est

Knight Therapeutics (TSX:GUD) projects fiscal year 2026 sales between $490 million and $510 million, surpassing the analyst estimate of $465.827 million. This indicates a positive outlook for the company's revenue growth in the upcoming fiscal year.